Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-Muscle Myosin II in Newly Diagnosed Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics has dosed the first patient in its Phase 1/2 glioblastoma trial, advancing the development of a potential new cancer therapy in collaboration with the Mayo Clinic and NCI.
Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Inc., which acquired UF Startup AavantiBio, has partnered with Mayo Clinic to advance an AAV gene therapy platform for next-generation treatments targeting genetic cardiomyopathies and channelopathies linked to sudden cardiac death.